









Narrative review of *Vitex agnus-castus* in symptoms in Gynecology

Ceci Mendes¹ , Angela Maggio da Fonseca¹ , Mayara Souza Alves¹ ,
Luiza Helena Costa Moreira Bayer¹ , Eduardo Carvalho de Arruda Veiga^{2*} ,
Isabel Cristiana Espósito Sorpreso¹ , Edmund Chada Baracat¹ , José Maria Soares Júnior¹ 

INTRODUCTION

Since ancient times, it is said that women can look different than usual, especially in the phase that precedes menstruation. Hippocratic texts mention tremors, fatigue, and pressure in the head. Romans cite torpor, nausea, and loss of appetite. The name “premenstrual tension” was given by Frank in 1931, based on the set of physical, psychological, and behavioral changes that appear in the period before menstruation and regress with it. In 1953, Greene and Dalton advised using the term “syndrome” instead of tension, as the condition is usually represented by a set of symptoms, with multiple variables and different aspects, depending on the affected people¹.

In 1987, the American Psychiatric Association defined “late luteal phase dysphoric disorder” as a mental disorder^{1,2}. This inclusion led to a great deal of discussion, along with several objections, as it represents the evident potential risk of using this diagnosis in criminal charges, in addition to promoting prejudice against the female sex. However, the diagnosis remains recorded in the manuals. At present, this disorder is considered a diagnosis only in very serious cases in which impairment of socialization and usual activity is evident.

Premenstrual syndrome is defined as a set of disorders with somatic, affective, cognitive, and behavioral manifestations that occur in the luteal phase of the menstrual cycle and disappear after menstruation, cyclic, recurrent, and sometimes disabling. One study found that only 3–15% of women have severe symptoms².

Due to the day-to-day implications, there is great interest in treating affected women, providing them with greater well-being and friendly coexistence. One of the treatment alternatives is to use the extracts of *Vitex agnus-castus*.

HISTORIC

In ancient Greece, about two millennia ago, Dioscorides describes *Vitex agnus-castus* as a medicinal plant. It is also called monk's pepper, chaste tree (or chasteberry in English), northern rosemary, and so on. Its name *Vitex agnus-castus* was derived from the Latin “chaste lamb”. Owing to its ability to reduce sexual desire, the monks used this plant to maintain their vow of chastity³.

This plant has been traditionally used for centuries to treat various female problems, such as cyclical breast tenderness, menstrual irregularities, and premenstrual tension⁴.

CHEMICAL COMPOSITION

Most of the studies were carried out with tinctures or extracts obtained from the fruits containing essential oils, iridoid glycosides, diterpenes, and flavonoids. Essential oils contain limonene, cineole, pinene, and sabinene; primary flavonoids include casticine (Figure 1), orientin, kaempferol, quercetagenin, and isovitexin; diterpenes consist of vitexilactone, rotundifuran, and 7-beta-diacetoxy-13-hydroxy-labda-8,14-diene; and iridoid glycosides include agnosidium (Figure 2) and aucubin (Figure 3). The agnoside is used as a quality marker of extracts. There is no accurate information on the presence of progesterone, 17-hydroxyprogesterone, testosterone, and epitestosterone^{4,5}.

PHARMACOLOGY

Vitex extract promotes a reduction in prolactinemia. This action results from the binding of components with dopaminergic properties to protein receptors⁶. There is evidence that shows binding to dopamine receptors in the hypothalamus and anterior

¹Universidade de São Paulo, Faculdade de Medicina – São Paulo (SP), Brazil.

²Universidade de São Paulo, Faculdade de Medicina – Ribeirão Preto (SP), Brazil.

*Corresponding author: eduveiga56@gmail.com

Conflicts of interest: the authors declare there is no conflicts of interest. Funding: none.

Received on February 17, 2022. Accepted on February 18, 2022.

pituitary and inhibiting the release of prolactin. There also seem to be other endocrine effects, such as increased progesterone secretion and induction of corpus luteum formation⁴.

The estrogenic activity of the ethanol extract was demonstrated in ovariectomized rats by promoting an increase in uterine volume, increasing the dosage of progesterone and estrogens, and also inducing a reduction in LH and prolactin⁷.

CLINICAL TRIALS

Premenstrual syndrome

A multicenter study with 1634 patients, observed during three menstrual cycles, using Vitex extract, answered a questionnaire about their psychic symptoms, and attributed to water retention; 93% of the patients reported symptomatic improvement, without significant adverse effects⁸.




Figure 1. Chemical structure of Casticine⁵.




Figure 2. Chemical Structure of Agnosidium⁵.




Figure 3. Chemical structure of Aucubin⁵.

A study on 170 patients (84 of them with the herbal medicine) during three menstrual cycles compared the efficacy of Vitex agnus-castus with placebo and found an important superiority of the herbal medicine ($p < 0.001$), with adverse events without seriousness but similar to the placebo group⁹ (Table 1).

With regard to therapeutic options (especially fluoxetine, sertraline, and Vitex), and the above findings, Carr considered the option of using agnus chaste very promising¹⁰.

Comparing the herbal medicine with fluoxetine, a study with 24 patients, during two cycles, did not observe a significant difference between treatments with fluoxetine and monk's pepper, although both improved the psychological and physical symptoms¹¹.

In a prospective, multicenter study conducted in China, compared with placebo, 202 patients completed 3 months of observation (101 using the extract). The symptom score was significantly lower in patients who used the active drug, leading to the conclusion that this treatment was effective, well-tolerated, and safe¹² (Table 2).

OTHER CLINICAL SITUATIONS

In a review of several studies, the reduction of breast tenderness by reducing prolactinemia is considered an excellent therapeutic option¹².

The immunomodulatory activity of casticin, a flavonoid from Vitex agnus-castus, has been demonstrated in vitro¹³.

The effect of a hydrophilic plant extract has also been described in rats to reduce epileptic seizures¹⁴.

The action in fertility regulation has been described for some time. A case of ovarian hyperstimulation attributed to

Table 1. Reduction of symptoms in two therapeutic groups.

Symptoms	Reduction of symptoms (%)	
	Vitex agnus-castus (n=86)	Placebo (n=84)
Headache	-17.8	-5.9
Irritability	-28.9	-18.2
Mood changes	-28.7	-17.6
Changes in breasts	-18.6	-9.4

Significance at $p < 0.001$.

Table 2. Therapeutic group scores for moderate-to-severe premenstrual syndrome in Chinese patients.

	Vitex agnus-castus (n=101)	Placebo (n=101)
Previous score	26.17	27.10
Final score	9.92	10.69

Significance at $p < 0.01$.

the use of *Vitex* has been described in a patient undergoing in vitro fertilization treatment¹⁵. In other circumstances, it was considered an alternative option to assist infertile couples¹⁶. A double-blind study comparing placebo and nutritional products with various components, including agno chaste, green tea, vitamins, and minerals, demonstrated a very significant increase in progesterone and elevation of basal temperature, regularization of menstrual cycles, and increase in the number of fertilization ($p=0.01$), without significant adverse effects¹⁷.

In a culture of human neoplastic cells of various types, the extract exerted a cytotoxic action, attributed to the intracellular oxidation activity of the treatment with the extract¹⁸. Its ability on the biology of prostate cells was also studied, concluding that the extracts may be useful in the treatment of not only prostate cancer but also benign hyperplasia¹⁹. In colon carcinoma, also in cell culture, treatment with this plant induced apoptosis, suggesting a mechanism of gene activation and proving to be a useful aid in the treatment of this type of cancer²⁰.

Its possible use in the treatment of problems linked to menopause may be of special interest nowadays. A study in cell culture demonstrates that phytoestrogens contained in the stratum of *Vitex agnus-castus* can exert actions mediated by estrogen receptors, and apigenin seems to be the most active of these compounds, such as vitexin and penduletin²¹. In vitro studies have also shown that linoleic acid from the fruits of this plant can bind to estrogen receptors and interfere with gene induction, with a protective effect on breast and endometrial cancer, which is desirable in the treatment of climacteric²². In rabbits, the action of flavonoids from agnus castus extract in the healing of bone fractures was demonstrated, a fact that may have implications for the treatment of osteoporotic women with fractures²³. Using a product with extracts from six plants, including *Vitex*, or placebo, for 3 months (50 patients between 44 and 55 years old), a progressive and marked improvement in climacteric symptoms was observed (47% with the product, 19% with placebo)²⁴. Another study in which 93 climacteric women ended 16 weeks using a product combining extracts of *Hypericum perforatum* and *Vitex agnus-castus*, or placebo, however, did not show a different effect between the groups, although no important adverse effects were found and tolerability was good²⁵.

Toxicology

Vitex agnus-castus is quite safe and has no significant toxic effects. The adverse effects cited are mild and reversible. As it is used in the treatment of women with premenstrual syndrome, as well as in the treatment of infertility, that is, women of childbearing age and possibly ovulatory, its use is likely to occur after fertilization. And no harm to the pregnancy or fetus

is reported. Its use during lactation to increase milk production has been reported in herbal medicine textbooks, but there are also reports of decreased lactation due to the suppressive action of prolactin. Although there are reports of progesteric, emmenagogue, and abortion-preventive activity, it is not clear whether or not its use during pregnancy is harmful since the scientific evidence is poor. . Therefore, caution is recommended regarding its use in pregnant or lactating women⁴.

Drug interactions

Agno casto should not be used in conjunction with drugs with dopaminergic action, such as bromocriptine and metoclopramide, or any other dopamine agonist. Also, it should not be associated with antipsychotic drugs. Caution is suggested when using hormonal contraceptives or during climacteric hormonal treatment⁴.

Adverse reactions

The adverse effects mentioned in the different studies with the plant are of low intensity and reversible. Erythematous rashes, acne, itching, headache, nausea, mild gastrointestinal complaints, fatigue, dry mouth, and menstrual disorders are the most common complaints. Nocturnal seizures occurred in a patient using a combination of herbs, including monk's pepper; however, this effect does not seem to be due to the use of plant⁴.

Contraindications

Due to its hypersensitivity reaction, *Vitex agnus-castus* is also contraindicated in pregnancy and breastfeeding women. Although there is no clinical evidence or reports of hormone interaction, based on theoretical grounds, caution is recommended when using *Vitex agnus-castus* with hormone therapy.

Indications

The main indications are irregularities of the menstrual cycle such as irregular bleeding, absence of menstruation, and decreased menstrual flow and premenstrual tension, especially if there are symptoms such as breast pain and fluid retention. Other indications include hyperprolactinemia, infertility due to low progesterone levels, or corpus luteum failure. In men, it is useful in cases of sexual frigidity and impotence⁵.

Posology

Based on the recommendations of the German Commission E, the recommended daily dose is 40 mg of *Vitex agnus-castus*, once a day, on an empty stomach.

Overdose

We found no references about overdose.

Prescription information

In cases of infertility, treatment is recommended for 5–7 months⁵.

In the case of premenstrual syndrome, the treatment must be carried out for at least 3 months, continuing even after the symptoms are relieved⁵.

AUTHORS' CONTRIBUTIONS

CM: Project administration, Data curation, Formal Analysis, Writing – original draft, Writing – review & editing. **AMF:**

Project administration, Data curation, Formal Analysis, Writing – review & editing. **MSA:** Project administration, Data curation, Formal Analysis, Writing – original draft, Writing – review & editing. **LHCMB:** Project administration, Data curation, Formal Analysis, Writing – original draft, Writing – review & editing. **ECAV:** Writing – original draft, Writing – review & editing. **ICES:** Writing – original draft, Writing – review & editing. **ECB:** Writing – original draft, Writing – review & editing. **JMSJ:** Project administration, Data curation, Formal Analysis, Writing – review & editing.

REFERENCES

- Diegoli, MSC. Síndrome Pré-menstrual: Aspectos Clínicos e Terapêuticos. [Tese Doutorado]. São Paulo (SP): Faculdade de Medicina da Universidade de São Paulo, 1997.
- ICE Sorpreso, JM Soares Júnior, AM Fonseca, EC Baracat. Female aging. *Revista da Associação Médica Brasileira* 61, 553-556.
- Schulz V, Hänzel R, Tyler VE. Indicações ginecológicas para medicamentos fitoterápicos. In: *Fitoterapia Racional*. 4th ed. São Paulo (SP): Manole; 2002. p. 292.
- Dugoua JJ, Seely D, Perri D, Koren G, Mills E. Safety and efficacy of chastetree (*Vitex agnus castus*) during pregnancy and lactation. *Can J Clin Pharmacol*. 2008;15(1):e74-9. PMID: 18204102
- Maia ACCM, Soares FCC, Martins Junior HB, Baptista ER. *Vitex agnus castus* L.: Um Estudo Etnobotânico e Etnofarmacológico. *Revista Virtual de Iniciação Acadêmica da UFPA*. Vol. 1. [cited on 2001 Julho]. Available from: <http://www.ufpa.br/revistaic>
- Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlová-Wuttke D. Chaste tree (*Vitex agnus castus*) – pharmacology and clinical indications. *Phytomedicine*. 2003;10(4):348-57. <https://doi.org/10.1078/09447110322004866>
- Ibrahim NA, Shalaby AS, Farag RS, Elbaroty GS, Nofal SM, Hassan EM. Gynecological efficacy and chemical investigation of *Vitex agnus castus* L. fruits growing in Egypt. *Nat Prod Res*. 2008;22(6):537-46. <https://doi.org/10.1080/14786410701592612>
- Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing *Vitex agnus castus*. *J Women Health Gend Based Med*. 2000;9(3):315-20. <https://doi.org/10.1089/152460900318515>
- Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. *BMJ*. 2001;322:134-7. <https://doi.org/10.1136/bmj.322.7279.134>
- Carr M. Selections from current literature treatments for premenstrual dysphoric disorder. *Family Practice*. 2001;18(6):644-6. <https://doi.org/10.1093/fampra/18.6.644>
- Atmaca M, Kumru S, Tezcan E. Fluoxetine versus *Vitex agnus castus* extract in the treatment of premenstrual dysphoric disorder. *Hum Psychopharmacol*. 2003;18(3):191-5. <https://doi.org/10.1002/hup.470>
- Carmichael AR. Can *Vitex agnus castus* be used for the treatment of mastalgia? What is the current evidence? *Evid Based Complement Alternat Med*. 2008;5(3):247-50. <https://doi.org/10.1093/ecam/hem074>
- Mesaik MA, Azizuddin MS, Khan KM, Tareen RB, Ahmed A, Attar-Rahman, et al., Isolation and immunomodulatory properties of a flavonoid, casticin from *Vitex agnus castus*. *Phytother Res*. 2009;23(11):1516-20. <https://doi.org/10.1002/ptr.2492>
- Saberi M, Rezvanizadeh A, Bakhtiarian A. The antiepileptic activity of *Vitex agnus castus* extract on amigdala kindled seizures in male rats. *Neurosci Lett*. 2008;441(2):193-6. <https://doi.org/10.1016/j.neulet.2008.06.034>
- Chill DJ, Fox R, Wardle PG, Harlow CR. Multiple follicular development associated with herbal medicine. *Hum Reprod*. 1994;9(8):1469-70. <https://doi.org/10.1093/oxfordjournals.humrep.a.138731>
- Veal L. Complementary therapy and infertility: an Icelandic perspective. *Complement Ther Nurs Midwifery*. 1998;4(1):3-6. <https://doi.org/10.1016/s1353-6117.98.80003-6>
- Westphal LM, Polan ML, Trant As. Double-blind placebo-controlled study of fertility blend: a nutritional supplement for improving fertility in women. *Clin Exp Obstet Gynecol*. 2006;33(4):205-8. PMID: 17211965
- Ohyama K, Akaike T, Hirobe C, Yamakawa T. Cytotoxicity apoptotic inducibility of *Vitex agnus castus* fruit extract in cultured human normal and cancer cells and effect on growth. *Biol Pharm Bull*. 2003;26(1):10-8. <https://doi.org/10.1248/bpb.26.10>
- Weisskopf M, Schaffner W, Jundt G, Suizer T, Wyler S, Tullberg-Reinert H. A *Vitex agnus castus* extract inhibits cell growth and induces apoptosis in prostate epithelial cell lines. *Planta Med*. 2005;71(10):910-6. <https://doi.org/10.1055/s-2005-871235>
- Imai M, Kikuchi H, Denda T, Ohyama K, Hirobe C, Toyoda H. Cytotoxic effects of flavonoids against human colon cancer derived cell line, COLO 201: a potential natural anti-cancer substance. *Cancer Lett*. 2009;276(1):74-80. <https://doi.org/10.1016/j.canlet.2008.10.036>
- Jarry H, Spengler B, Porzel A, Schmidt J, Wuttke W, Christoffel V. Evidence for estrogen receptor beta-selective activity of *Vitex agnus castus* and isolated flavones. *Planta Med*. 2003;69(10):945-7. <https://doi.org/10.1055/s-2003-45105>
- Liu J, Burdette JE, Sun Y, Deng S, Schlecht SM, Zheng W, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of *Vitex agnus castus* L (Chaste-berry). *Phytomedicine*. 2004;11(1):18-23. <https://doi.org/10.1078/0944-7113-00331>
- Oztürk A, Ilman AA, Saglam H, Yaçinkaya U, Aykut S, Akgöz S, et al. The effects of phytoestrogens on fracture healing: experimental research in New Zealand white rabbits. *Ulus Travma Acil Cerrahi Derg*. 2008;14(1):21-7. PMID: 18306063
- Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flashes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. *Gynecol Endocrinol*. 2007;23(2):117-22. <https://doi.org/10.1080/09513590701200900>
- van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. *Hypericum perforatum* with *Vitex agnus castus* in menopausal symptoms: a randomized, controlled trial. *Menopause*. 2009;16(1):156-63. <https://doi.org/10.1097/gme.0b013e31817fa9e0>

